Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ginkgo Bioworks Holdings, Inc. Class A Common Stock (NY: DNA )

11.39 -1.43 (-11.15%)
Streaming Delayed Price Updated: 1:10 PM EST, Jan 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ginkgo Bioworks Holdings, Inc. Class A Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
NYSE:DNA Long Term Investor Alert: Investigation of Potential Wrongdoing at Ginkgo Bioworks Holdings, Inc.
San Diego, CA -- (SBWIRE) -- 04/13/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Ginkgo Bioworks Holdings, Inc. 
Via SBWire
Elanco, Ginkgo Bioworks Launch BiomEdit, Microbiome-Focused Animal Health Firm
Elanco Animal Health Incorporated (NYSE: ELAN) and Ginkgo Bioworks Holdings Inc (NYSE: DNA) have launched BiomEdit, a microbiome innovation company.... 
Via Benzinga
Baillie Gifford Just Bought Ginkgo Bioworks (DNA) Stock. Here’s Why.
Baillie Gifford recently disclosed that it purchased 48.8 million shares of DNA stock on March 31. The firm has a $180 billion portfolio. 
Via InvestorPlace
Twist Bioscience and Ginkgo Bioworks Sign New Collaboration
From Twist Bioscience Corporation
Via Business Wire
Ginkgo Bioworks Shares Gain As Q4 Sales, FY22 Guidance Surpass Street Expectations
Ginkgo Bioworks Holdings Inc (NYSE: DNA) reported  
Via Benzinga
Why BofA Sees 'Better Entry Point' In Ginkgo Bioworks Stock
Ginkgo Bioworks Holdings Inc (NYSE: DNA) is “at the forefront of the rising SynBio wave, a market we think holds much long-term promise,” according to BofA Securities. 
Via Benzinga
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. 
Via Benzinga
Looking Into Ginkgo Bioworks Holdings's Recent Short Interest
Ginkgo Bioworks Holdings's (NYSE:DNA) short percent of float has risen 9.65% since its last report. The company recently reported that it has 81.30 million shares sold short,... 
Via Benzinga
7 Growth Stocks to Buy on the Dip
Although the wave of red ink in the major indices is intimidating, it also presents an intriguing opportunity for growth stocks to buy. 
Via InvestorPlace
Cathie Wood Keeps Buying Gingko Bioworks (DNA) Stock. Here’s Why.
DNA stock is in the spotlight after Ark Invest reported purchasing more than 1.5 million shares this week. So, who else is betting big on Ginkgo? 
Via InvestorPlace
7 Biggest Loser Stocks That Could Become Surprising Buys
A huge pouring of red ink can sometimes lead to extraordinary gains, though you’ve got to be aware of the risks. 
Via InvestorPlace
28 Biggest Movers From Yesterday
Gainers HighPeak Energy, Inc. (NASDAQ: HPK) shares gained 31.76% to close at $28.83 on Wednesday, after CNBC’s Jim Cramer said the mid-cap company is an aggressive play on... 
Via Benzinga
Why Is Ginkgo Bioworks (DNA) Stock Up Today?
Biotechnology company Ginkgo Bioworks has a host of promising collaboration announcements. DNA stock is up as a result. 
Via InvestorPlace
53 Biggest Movers From Yesterday
Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) shares gained 96.7% to settle at $29.49 on Tuesday. Sanofi SA (NASDAQ: SNY) and IGM Biosciences signed an exclusive worldwide... 
Via Benzinga
36 Stocks Moving In Tuesday's Mid-Day Session
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) jumped 88.1% to $0.38 after declining 9% on Monday. McCormick (NASDAQ: IGMS) shares jumped 49.8% to $22.46. Sanofi SA (... 
Via Benzinga
Here's Why Ginkgo Bioworks Shares Are Rising
Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher by 22.0% at $4.56 after the company reported better-than-expected fourth-quarter sales results and issued FY22 sales guidance above... 
Via Benzinga
Is DNA Stock a Buy After Earnings? 3 Analysts Weigh In on Gingko Bioworks.
DNA stock is bouncing higher following a better-than-expected earnings report and strong forward guidance from Gingko Bioworks. 
Via InvestorPlace
8 Materials Stocks Moving In Tuesday's Pre-Market Session
Gainers Ginkgo Bioworks Holdings (NYSE:DNA) shares rose 9.9% to $4.11 during Tuesday's pre-market session. The market value of their outstanding shares is at $6.8 billion. The company's, Q4 earnings... 
Via Benzinga
Why Ginkgo Bioworks Stock Is Rising After Hours
Ginkgo Bioworks Holdings Inc (NYSE: DNA) is trading higher in Monday's after-hours session after the company reported financial results and issued guidance above estimates.  
Via Benzinga
Earnings Scheduled For March 28, 2022
Companies Reporting Before The Bell • LGL Group (AMEX:LGL) is likely to report quarterly earnings at $0.10 per share on revenue of $7.20 million. 
Via Benzinga
Ginkgo Bioworks Adds Ultra-High-Throughput Screening Platform Via FGen Acquisition
Ginkgo Bioworks Holdings Inc (NYSE: DNA) has agreed to acquire FGen AG, a Swiss company specializing in strain development and optimization. Under the... 
Via Benzinga
23 Stocks That Have Sold Off Hard Since The Russia-Ukraine War Began
The S&P 500 is having a rough start to 2022, down 11.27% year to date. Since Russia invaded Ukraine on Feb. 24, the S&P 500 has fallen an additional 0.78%. Following are... 
Via Benzinga
7 Stocks to Buy After Sentiment Slipped to Lows
With sentiment souring over inflation and other concerns, contrarians may have an opportunity to bank on certain stocks to buy like these. 
Via InvestorPlace
Did Going Public Give This Company Momentum? Stran & Company Closes First Acquisition; Adds Over $7 Million in Annualized Revenue
Photo by Catkin on Pixabay This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Some... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 2, 2022
Upgrades Barclays upgraded the previous rating for Equitrans Midstream Corp (NYSE:ETRN) from Underweight to Equal-Weight. Equitrans Midstream earned $0.07 in the fourth... 
Via Benzinga
Ginkgo Bioworks Announces Acquisition Of Massachusetts COVID-19 Testing Provider Project Beacon COVID-19 LLC; Terms Not Disclosed
Acquisition to enable Ginkgo to bolster its growing biosecurity platform and provide expanded COVID-19 testing options to communities in Massachusetts and beyond BOSTON, Jan. 19,... 
Via Benzinga
Final Deadline Alert: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
DNA; SRNG Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Ginkgo Bioworks Holdings Inc. (f/k/a Soaring Eagle Acquisition Corp.) Investors With Losses Exceeding $200K of Class Action
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Deadline Tomorrow Alert: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
GINKGO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.